A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: Rifampin; Drug: CC-92480; Drug: Itraconazole; Drug: Digoxin; Drug: Rosuvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT05389722

CA057-002

Details and patient eligibility

About

The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

Enrollment: 24 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Must have a body mass index between 18 and 33 kg/m2 (inclusive)
• Adult female of nonchildbearing potential or male, any race or ethnicity, and in good health as determined by the medical history, physical exam, vital signs, 12-lead electrocardiogram, and clinical laboratory assessments

Exclusion criteria

• Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion
• Any major surgery within 4 weeks of the first dose administration
• History of drug abuse within 2 years of the first dose administration

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

24 participants in 3 patient groups

Part 1

Experimental group

Treatment:

Drug: Rifampin

Drug: CC-92480

Part 2

Experimental group

Treatment:

Drug: Itraconazole

Drug: CC-92480

Part 3

Experimental group

Treatment:

Drug: Rosuvastatin

Drug: Digoxin

Drug: CC-92480